Sanjay Chanda
CIK 1571820 · Chief Development Officer · last filed 2026-03-23
Sanjay Chanda is a Chief Development Officer who has filed 17 SEC Form 4 insider transactions across 2 companies since 2013. The most recent filing, for ANTX, was dated Mar 23, 2026. Across all open-market trades the lifetime net is −$655.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $563.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$563.2K
2
17
-$655.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANTX | Chief Development Officer | 118,823 | $4.74 | $563.2K | -$13.3K | 9 | 2026-03-23 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | SVP, Drug Development | 34,039 | $10.19 | $346.9K | -$642.5K | 8 | 2015-03-04 |
Recent Filings
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-23 | ANTX | Mixed | — | $0 | EDGAR |
| 2026-02-23 | ANTX | Grant (A) | +38,000 | $0 | EDGAR |
| 2026-01-07 | ANTX | Sell (S) | −9,251 | -$9.3K | EDGAR |
| 2025-02-28 | ANTX | Grant (A) | +50,250 | $0 | EDGAR |
| 2025-01-07 | ANTX | Sell (S) | −2,957 | -$4.0K | EDGAR |
| 2024-03-29 | ANTX | Grant (A) | +27,500 | $0 | EDGAR |
| 2024-03-18 | ANTX | Grant (A) | +27,500 | $0 | EDGAR |
| 2023-02-17 | ANTX | Grant (A) | — | $0 | EDGAR |
| 2022-05-16 | ANTX | Grant (A) | — | $0 | EDGAR |
| 2015-03-04 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Mixed | — | -$188.7K | EDGAR |